Shield expecting US decision on Feraccru in July
Shield Therapeutics has revealed that the US Food and Drug Administration will make a decision on its application to market Feraccru in the US by July 27 next year.
Read More
Tag: iron
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
